Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
Quince Therapeutics, Inc. (QNCX)
Company Research
Source: Seeking Alpha
eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment. QNCX has sufficient cash through the NEAT readout, plans for platform expansion, and has a commercialization partnership with Option Care Health. Ca-ssis/iStock via Getty Images Thesis Quince Therapeutics ( QNCX ) is doing a Phase 3 trial in Ataxia-Telangiectasia [A-T], an orphan disease without known treatment affecting 10,000 patients worldwide. Its Phase 3 trial called NEAT addresses issues related to failure in This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of QNCX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for i
Show less
Read more
Impact Snapshot
Event Time:
QNCX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNCX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNCX alerts
High impacting Quince Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QNCX
News
- Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-TelangiectasiaBusiness Wire
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders [Yahoo! Finance]Yahoo! Finance
QNCX
Earnings
- 11/12/25 - Miss
QNCX
Analyst Actions
- 1/6/26 - Citigroup Inc.
QNCX
Sec Filings
- 12/29/25 - Form 144
- 12/29/25 - Form 4
- 12/29/25 - Form 4
- QNCX's page on the SEC website